"Precision metagenomics" and "geospatially informed medical care" are among the long-term goals of the $5 million WorldQuant Initiative for Quantitative Prediction at Weill Cornell Medicine.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
Snyder's new book, "Genomics and Personalized Medicine," serves as a primer for patients and doctors, touching on topics from tailored cancer therapy to wearable devices.
Though cancer experts noted many tests under MEDCAC review were developed to be predictive of treatment response, CMS maintained the meeting's focus on the prognostic context.
The HIV Treatment Response Prediction System averages the output of four trained random forest models to predict response to antiretroviral drugs based on viral load, CD4 counts, HIV genotypes, and records of antiretroviral drug treatments.
The patents add to others held by Myriad covering pancreatic cancer markers.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.